Value Sense
CABA
Cabaletta Bio, Inc. (CABA)
Last Price$1.7(7.7%)
Market Cap$85.9M
LTM EPS
($2.17)
EPS growth
41.7%
Ben Graham Fair Value
($171.2)
Overvalued (Ben Graham formula)
(10,350.6%)
Stock quality
6/10
Good
CABA
is 528.8% undervalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

CABA Ben Graham Fair Value

Ben Graham Fair Value
Ben Graham Revised Fair Value

Ben Graham Fair Value Assumptions

as of Mar 09, 2025
EPS
($2.17)
P/E Base for no-growth company
8.5x
EPS growth
41.7%
Average Yield of AAA Corporate Bonds
4.4%
Current Yield of AAA Corporate Bonds
5.1%
Last share price
$1.7
Ben Graham Fair Value (local)
($171.2)
Ben Graham Fair Value
($171.2)
10350.6% overvalued

Ben Graham Fair Value Calculation

EPS
($2.17)
x
(
P/E base for no-growth
8.5x
+
2
x
EPS growth
41.7%
)
x
Average AAA
Bond Yield
4.4%
/
Current AAA Bond Yield
5.1%
=
Ben Graham Fair Value
($171.2)

Best stock ideas on the market right now

With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Low P/E stocks

Low P/E stocks

Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.

3M Return 7.5%
S&P Outperformance -5.5%
Next 3M Predicted Return 10.2%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%

CABA EPS growth & Dividend Yield

Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
EPS growth
Dividend Yield

CABA vs Peer Set: Ben Graham Fair Value Comparison

Ben Graham Fair Value
Ben Graham Revised Fair Value

GENERAL

BEN GRAHAM FAIR VALUE

FINANCIALS

Company name

Undervaluation / Overvaluation

Revenue growth

EPS growth

Net Income margin

Cabaletta Bio, Inc. logo
Cabaletta Bio, Inc.CABA
(10,350.6%)
N/A
(6.8%)
N/A
Median Peer Set
23.0%
(56.5%)
0.8%
Incyte Corporation logo
Incyte CorporationINCY
2,019.5%
14.8%
(94.0%)
0.8%
Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals IncorporatedVRTX
619.3%
11.7%
N/A
(4.9%)
BioNTech SE logo
BioNTech SEBNTX
499.6%
(77.4%)
(89.7%)
24.4%
United Therapeutics Corporation logo
United Therapeutics CorporationUTHR
106.7%
23.6%
25.7%
41.5%
BeiGene, Ltd. logo
BeiGene, Ltd.BGNE
82.3%
73.7%
(56.5%)
(35.9%)
Novo Nordisk A/S logo
Novo Nordisk A/SNVO
66.9%
24.9%
142.8%
34.8%
Regeneron Pharmaceuticals, Inc. logo
Regeneron Pharmaceuticals, Inc.REGN
40.8%
8.3%
10.4%
31.1%
Alnylam Pharmaceuticals, Inc. logo
Alnylam Pharmaceuticals, Inc.ALNY
(22.0%)
23.0%
(38.6%)
(12.4%)
argenx SE logo
argenx SEARGX
(32.9%)
198.6%
(60.5%)
(24.1%)
Summit Therapeutics Inc. logo
Summit Therapeutics Inc.SMMT
(122.2%)
N/A
(68.7%)
N/A

Explore more intrinsic value tools hub for CABA

Peter Lynch Fair Value
Reverse DCF
Earnings growth model
Earnings Power Value
Discount rate
Relative Value
Intrinsic Value
Margin of safety
DCF value calculator
Peter Lynch charts

FAQ

What is Cabaletta Bio, Inc.'s fair value according to the Ben Graham formula?

As of Sep 30, 2024, Cabaletta Bio, Inc.'s fair value using the Ben Graham formula is ($171.2) per share. This is calculated using Ben Graham formula, where EPS is ($2.2) and BVPS (Book Value Per Share) is $3.5. The current price of $1.7 suggests Cabaletta Bio, Inc. may be overvalued by this conservative metric.

What is Cabaletta Bio, Inc. earnings per share (EPS)?

Cabaletta Bio, Inc. earnings per share (EPS) for the twelve months ending Sep 30, 2024, was ($2.2), a 41.7% growth year-over-year.

What is Cabaletta Bio, Inc.'s margin of safety based on the Ben Graham analysis?

Cabaletta Bio, Inc.'s margin of safety is negative 10,350.6%, calculated as (Graham Number - Current Price) / Current Price. A negative margin of safety suggests the stock doesn't provide the level of safety Graham typically sought in his investments.